e may increase the risk for QT prolongation.
Panobinostat: (Major) Avoid coadministration of ribociclib with panobinostat due to an increased risk for QT prolongation. Systemic exposure of panobinostat may also be increased resulting in increase in treatment-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner; QT prolongation has also been reported with panobinostat therapy in patients with multiple myeloma in a clinical trial. Concomitant use may increase the risk for QT prolongation. Ribociclib is also a moderate CYP3A4 inhibitor and panobinostat is a CYP3A4 substrate.
Paricalcitol: (Moderate) Use caution if coadministration of ribociclib with paricalcitol is necessary, as the systemic exposure of paricalcitol may be increased resulting in increase in treatment-related adverse reactions. Monitor plasma PTH and serum calcium and phosphorous concentrations if a patient initiates or discontinues therapy with this combination. Ribociclib is a moderate CYP3A4 inhibitor and paricalcitol is a CYP3A4 substrate.
Pasireotide: (Major) Avoid coadministration of ribociclib with pasireotide due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Pasireotide has also been associated with QT prolongation. Concomitant use may increase the risk for QT prolongation.
Pazopanib: (Major) Avoid coadministration of ribociclib with pazopanib due to an increased risk for QT prolongation. Additionally, the systemic exposure of both drugs may be increased resulting in an increase in treatment-related adverse reactions (e.g., neutropenia, QT prolongation). Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Pazopanib has also been associated with QT prolongation. Concomitant use may increase the risk for QT prolongation. Ribociclib is also extensively metabolized by CYP3A4 and is a moderate CYP3A4 inhibitor; pazopanib is a weak CYP3A4 inhibitor and CYP3A4 substrate.
Pentamidine: (Major) Avoid coadministration of ribociclib with pentamidine due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Systemic pentamidine has also been associated with QT prolongation. Concomitant use may increase the risk for QT prolongation.
Pentobarbital: (Moderate) Use caution if ribociclib is coadministered with pentobarbital, as ribociclib exposure may decrease resulting in reduced efficacy. Ribociclib is extensively metabolized by CYP3A4, and pentobarbital is a CYP3A4 inducer. Coadministration with a strong CYP3A4 inducer decreased the ribociclib AUC and Cmax by 89% and 81%, respectively, in healthy volunteers; other CYP3A4 inducers may also decrease ribociclib exposure.
Perampanel: (Moderate) Use caution if coadministration of ribociclib with perampanel is necessary, as the systemic exposure of perampanel may be increased resulting in increase in treatment-related adverse reactions. Exposure to ribociclib may also decrease, resulting in decreased efficacy. Ribociclib is extensively metabolized by CYP3A4 and is also a moderate CYP3A4 inhibitor; perampanel is a CYP3A4 substrate and a weak CYP3A4 inducer.
Perindopril; Amlodipine: (Moderate) Use caution if coadministration of ribociclib with amlodipine is necessary, as the systemic exposure of amlodipine may be increased resulting in an inc |
